Management of toxoplasmic encephalitis in HIV-infected adults
Sübutlu məlumatların xülasələri
09.07.2015 • Sonuncu dəyişiklik 09.07.2015
Editors
There appears to be no significant differences in the effects of pyrimethamine plus sulfadiazine versus pyrimethamine plus clindamycin or trimethoprim-sulfamethoxazole on mortality or cure rates in the management of toxoplasmic encephalitis in HIV-infected adults.
A Cochrane review included 3 studies with a total of 335 subjects. Two trials compared pyrimethamine plus sulfadiazine (P+S) with pyrimethamine plus clindamycin (P+C). One trial compared P+S with trimethoprim-sulfamethoxazole (TMP-SMX). All three studies were relatively small and did not show significant differences in the treatment effects between the different drug regimens.
Comment: The quality of evidence is downgraded by imprecise results (limited study size for each comparison).
Ədəbiyyat
- Dedicoat M, Livesley N. Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings). Cochrane Database Syst Rev 2006 Jul 19;3:CD005420.